Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20950754 | 0.82 | CLK4 (0.50) | CLK4KMT2ANPC1RAB9AHTT | |
| SCHEMBL14330643 | 0.82 | CLK4 (0.56) | CLK4KMT2ANPC1RAB9AHTT | |
| SCHEMBL27103118 | 0.78 | EGFR (0.51) | CLK4KMT2ANPC1RAB9ADYRK1A | |
| SCHEMBL30236327 | 0.78 | EGFR (0.51) | CLK4KMT2ANPC1RAB9ADYRK1A | |
| SCHEMBL1136800 | 0.76 | HTT (0.54) | CLK4KMT2ANPC1RAB9AHTT | |
| SCHEMBL24460958 | 0.76 | CLK4 (0.53) | CLK4KMT2ANPC1RAB9AHTT | |
| SCHEMBL26459069 | 0.75 | NPC1 (0.50) | CLK4KMT2ANPC1RAB9AHTT | |
| SCHEMBL20489500 | 0.74 | MAPT (0.57) | CLK4KMT2ANPC1RAB9AHTT | |
| SCHEMBL21805769 | 0.74 | NPC1 (0.61) | CLK4KMT2ANPC1RAB9AHTT | |
| SCHEMBL5416533 | 0.74 | CLK4 (0.52) | CLK4KMT2ANPC1RAB9ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127370-A1 | DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DKK1, WNT1 | CLK4 383/4885KMT2A 1066/4885NPC1 4572/4885 |
| US-10703748-B2 | Diazanaphthalen-3-yl carboxamides and preparation and use thereof | DYRK1A, DKK1, WNT1 | CLK4 383/4885KMT2A 1066/4885NPC1 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.